Dare Bioscience Inc

-0.04 (-3.57%)
Products, Regulatory

Organon Enters Into Global License Agreement To Commercialize Daré Bioscience’s Xaciato (Clindamycin Phosphate Vaginal Gel, 2%)

Published: 03/31/2022 12:03 GMT
Dare Bioscience Inc (DARE) - Organon Enters Into Global License Agreement to Commercialize DarÉ Bioscience’s Xaciato™ (clindamycin Phosphate Vaginal Gel, 2%), FDA-approved Treatment for Females 12 and Older With Bacterial Vaginosis (bv).
Organon & Co - DarÉ Will Receive a $10 Million Upfront Payment From Organon.
Organon & Co - DarÉ is Eligible to Receive Potential Milestone Payments of Up to $182.5 Million and Tiered Double-digit Royalties Based on Net Sales.
Organon & Co - Xaciato is Expected to Be Available Commercially in U.S. in Q4 2022.